Pancreatic Enzyme Replacement Therapy: Drugs

The Department is currently managing a supply issue with the pancreatic enzyme replacement therapy (PERT) Creon, which is used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic cancer and neuroendocrine cancer. The supply issue with Creon is impacting countries throughout Europe and has been caused by the limited availability of raw ingredients and manufacturing capacity constraints to produce the volumes needed to meet demand. This is causing knock-on supply issues with alternative PERT products.

The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production. Through these discussions we have managed to secure additional volumes for 2025 for the United Kingdom.

The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. In May 2024, pancreatin preparations were added to the Department’s list of medicines that cannot be exported from the UK or hoarded. In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.

The Department has widely disseminated comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply to ensure that no patient is left without PERT.